|
gptkbp:instanceOf
|
gptkb:drug
antipsychotic medication
|
|
gptkbp:approvedBy
|
1997
|
|
gptkbp:ATCCode
|
N05AH04
|
|
gptkbp:availableOn
|
gptkb:tablet
extended-release tablet
|
|
gptkbp:bioavailability
|
9%
|
|
gptkbp:brand
|
gptkb:Seroquel
gptkb:Seroquel_XR
|
|
gptkbp:CASNumber
|
111974-69-7
|
|
gptkbp:chemicalFormula
|
C21H25N3O2S
|
|
gptkbp:contraindication
|
hypersensitivity to quetiapine
|
|
gptkbp:discoveredBy
|
gptkb:AstraZeneca
|
|
gptkbp:eliminationHalfLife
|
6 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
quetiapine
|
|
gptkbp:KEGGID
|
D08445
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist
|
|
gptkbp:MedlinePlusID
|
a698019
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
gptkb:norquetiapine
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
83%
|
|
gptkbp:PubChem_CID
|
5002
CHEMBL716
DB01224
|
|
gptkbp:riskFactor
|
gptkb:cataracts
gptkb:metabolic_syndrome
seizures
suicidal thoughts
neuroleptic malignant syndrome
tardive dyskinesia
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:orthostatic_hypotension
constipation
dizziness
weight gain
QT prolongation
drowsiness
dry mouth
extrapyramidal symptoms
increased appetite
hyperglycemia
elevated cholesterol
|
|
gptkbp:UNII
|
RV60B5Y17N
|
|
gptkbp:usedFor
|
gptkb:generalized_anxiety_disorder
gptkb:major_depressive_disorder
bipolar disorder
schizophrenia
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|